We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+21.5%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.75B
AUM Growth
+$332M
Cap. Flow
-$28.9M
Cap. Flow %
-0.5%
Top 10 Hldgs %
51.71%
Holding
444
New
223
Increased
65
Reduced
45
Closed
77

Top Buys

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$54.6M
2
KYTX icon
Kyverna Therapeutics
KYTX
+$40.8M
3
SGRY icon
Surgery Partners
SGRY
+$33.8M
4
LRMR icon
Larimar Therapeutics
LRMR
+$33.4M
5
ALHC icon
Alignment Healthcare
ALHC
+$30.6M

Top Sells

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$62.6M
2
SWTX
SpringWorks Therapeutics
SWTX
+$60.2M
3
BAX icon
Baxter International
BAX
+$55M
4
VKTX icon
Viking Therapeutics
VKTX
+$36.3M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$28.1M

Sector Composition

Rank Sector Weight
1 Healthcare 88.87%
2 Industrials 0.71%
3 Technology 0.31%
4 Consumer Discretionary 0.26%
5 Financials 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRVL icon
276
Marvell Technology
MRVL
$147B
$261K ﹤0.01%
3,687
-1,361
-27% -$93.2K
TRN icon
277
Trinity Industries
TRN
$2.92B
$260K ﹤0.01%
9,329
-2,492
-21% -$64.2K
SF
278
Stifel
SF
$12.4B
$259K ﹤0.01%
+4,970
New +$245K
UE icon
279
Urban Edge Properties
UE
$2.9B
$259K ﹤0.01%
+14,991
New +$259K
ECVT icon
280
Ecovyst
ECVT
$1.32B
$259K ﹤0.01%
+23,217
New +$220K
MRSN
281
DELISTED
Mersana Therapeutics
MRSN
$258K ﹤0.01%
+2,299
New +$229K
MS icon
282
Morgan Stanley
MS
$319B
$257K ﹤0.01%
+2,734
New +$241K
PGNY icon
283
Progyny
PGNY
$2.46B
$256K ﹤0.01%
+6,708
New +$254K
ECL icon
284
Ecolab
ECL
$79.8B
$256K ﹤0.01%
1,107
-95
-8% -$20.1K
XRAY icon
285
Dentsply Sirona
XRAY
$2.84B
$255K ﹤0.01%
+7,690
New +$263K
CAH icon
286
Cardinal Health
CAH
$53.7B
$255K ﹤0.01%
+2,276
New +$246K
CRMT icon
287
America's Car Mart
CRMT
$25.9M
$254K ﹤0.01%
+3,977
New +$252K
CPB icon
288
Campbell Soup
CPB
$6.85B
$253K ﹤0.01%
+5,701
New +$247K
TOIIW
289
The Oncology Institute Warrant
TOIIW
$4.35M
$250K ﹤0.01%
1,250,000
– –
MRNA icon
290
Moderna
MRNA
$21.6B
$249K ﹤0.01%
+2,337
New +$236K
GOOGL icon
291
Alphabet (Google) Class A
GOOGL
$4.12T
$248K ﹤0.01%
+1,644
New +$235K
VC icon
292
Visteon
VC
$2.85B
$248K ﹤0.01%
2,108
-1,695
-45% -$198K
NGL icon
293
NGL Energy Partners
NGL
$1.94B
$247K ﹤0.01%
+42,830
New +$244K
NRIX icon
294
Nurix Therapeutics
NRIX
$2.45B
$243K ﹤0.01%
16,517
+799
+5% +$8.59K
UNH icon
295
UnitedHealth
UNH
$382B
$242K ﹤0.01%
+490
New +$249K
MBC icon
296
MasterBrand
MBC
$1.09B
$240K ﹤0.01%
12,830
-9,772
-43% -$155K
FLGT icon
297
Fulgent Genetics
FLGT
$558M
$238K ﹤0.01%
10,959
+1,130
+11% +$28.1K
MTD icon
298
Mettler-Toledo International
MTD
$28.1B
$236K ﹤0.01%
177
-61
-26% -$75.2K
ENLC
299
DELISTED
ENLINK MIDSTREAM, LLC
ENLC
$236K ﹤0.01%
17,269
+6,594
+62% +$81.7K
CCCC icon
300
C4 Therapeutics
CCCC
$389M
$234K ﹤0.01%
+28,590
New +$222K
10 11
12
13 14

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q1 2024 Portfolio in Review

As of Q1 2024, Deerfield Management held 444 positions worth $5.75B, up 6.1% from $5.42B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Deerfield Management's Q1 2024 filing shows 223 new, 65 increased, 45 reduced and 77 closed positions. Its largest new stake was BioNTech: 569,574 shares worth $52.5M. The largest sale was RayzeBio, Inc. Common Stock, an estimated $62.6M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 78% a quarter earlier, followed by Industrials and Technology.

  • Deerfield Management's largest Q1 2024 buy was BioNTech: 569,574 shares worth $52.5M.
  • Deerfield Management added most to Surgery Partners in Q1 2024, an estimated $33.8M increase.
  • Deerfield Management's biggest Q1 2024 reduction was SpringWorks Therapeutics, cutting an estimated $60.2M.
  • Deerfield Management fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $62.6M.
  • Deerfield Management's ten largest holdings make up 52% of its $5.75B portfolio in Q1 2024.
  • Deerfield Management opened 223 new positions and closed 77 in Q1 2024.
  • Deerfield Management's portfolio value rose 6.1% quarter-over-quarter to $5.75B.

Based on Deerfield Management's 13F filing for Q1 2024, filed 15 May 2024.